Update shared on 30 Nov 2025
Analysts have slightly raised their price target for AptarGroup to $161.43, citing a modest increase in expected profit margins as well as an updated outlook on revenue growth and future price-to-earnings ratios.
What's in the News
- Between July and September 2025, AptarGroup completed the repurchase of over 1.5 million shares for approximately $227.34 million as part of its ongoing buyback program (Company Filing).
- Nasus Pharma Ltd. extended its collaboration with AptarGroup by executing new agreements to advance the development and commercialization of its intranasal Epinephrine program. The agreements include updated terms and milestone payments (Company Announcement).
- Aptar France and AptarGroup are supporting Nasus Pharma's clinical development and planned commercialization of the NS002 intranasal epinephrine product candidate. This collaboration leverages Aptar's manufacturing capabilities for global regulatory submissions (Company Announcement).
- AptarGroup declared an almost 7% increase in its quarterly dividend, raising it to $0.48 per share. The new annualized dividend totals $1.92 per share and is effective for stockholders of record as of October 23, 2025 (Company Filing).
- At Investor Day 2025, AptarGroup reiterated its focus on pursuing bolt-on acquisitions to drive future growth (Management Statement).
Valuation Changes
- Consensus Analyst Price Target remains unchanged at $161.43 per share.
- Discount Rate has decreased marginally to 6.96%.
- Revenue Growth assumptions have fallen to 4.70% from previous estimates of 5.42%.
- Net Profit Margin has risen slightly to 10.26%.
- Future P/E ratio has increased modestly to 28.85x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.